GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicapsys Life Sciences Inc (OTCPK:VICP) » Definitions » Debt-to-EBITDA

Vicapsys Life Sciences (Vicapsys Life Sciences) Debt-to-EBITDA : -0.33 (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is Vicapsys Life Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vicapsys Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.31 Mil. Vicapsys Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Vicapsys Life Sciences's annualized EBITDA for the quarter that ended in Sep. 2023 was $-0.92 Mil. Vicapsys Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.33.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Vicapsys Life Sciences's Debt-to-EBITDA or its related term are showing as below:

VICP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.25   Med: -1.4   Max: -0.43
Current: -0.43

During the past 6 years, the highest Debt-to-EBITDA Ratio of Vicapsys Life Sciences was -0.43. The lowest was -2.25. And the median was -1.40.

VICP's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs VICP: -0.43

Vicapsys Life Sciences Debt-to-EBITDA Historical Data

The historical data trend for Vicapsys Life Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicapsys Life Sciences Debt-to-EBITDA Chart

Vicapsys Life Sciences Annual Data
Trend Dec08 Dec09 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial -2.25 - - - -

Vicapsys Life Sciences Quarterly Data
Jun10 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.48 -0.33

Competitive Comparison of Vicapsys Life Sciences's Debt-to-EBITDA

For the Biotechnology subindustry, Vicapsys Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicapsys Life Sciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicapsys Life Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vicapsys Life Sciences's Debt-to-EBITDA falls into.



Vicapsys Life Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vicapsys Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.613
=0.00

Vicapsys Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.307 + 0) / -0.92
=-0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Vicapsys Life Sciences  (OTCPK:VICP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Vicapsys Life Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vicapsys Life Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicapsys Life Sciences (Vicapsys Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
7778 Mcginnis Ferry Road, Suite 270, Suwanee, GA, USA, 30024
Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product name VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.
Executives
Moore Bobby M Jr 10 percent owner 4125 S.B. MERRION ROAD, LAKELAND FL 33810
Robert Grammen 10 percent owner 9180 GALLENA COURT, NAPLES FL 34109
Michael Yurkowski director 1505 ELM STREET, #1504, DALLAS TX 75201
William P. Esping 10 percent owner 2828 ROUTH STREET, SUITE 500, DALLAS TX 75201
Rodger Rees director C/O BONDS.COM GROUP, INC., 1515 SOUTH FEDERAL HIGHWAY, SUITE 212, BOCA RATON FL 33432
Mark Feldmesser director 641 UNIVERSITY BLVE, JUPITER FL 33458
Federico Pier director 1004 PLUM DRIVE, IRVING TX 75063
Ryan Seddon director, 10 percent owner 8120 BELVEDERE ROAD, SUITE 4, WEST PALM BEACH FL 33411

Vicapsys Life Sciences (Vicapsys Life Sciences) Headlines

From GuruFocus